Sign Up
Stories
Anocca Appoints Martin Welschof to Board of Directors
Share
AB-2100 Phase 1/2 Trial Initiated
Adagene Advances Clinical Collaboration
Advancements in Cancer Treatment and Mar...
Advancing CD70 Targeted Cancer Treatment...
Affini-T Therapeutics at J.P. Morgan Hea...
Anktiva Boosts Lung Cancer Treatment
Overview
API
Anocca AB appoints Martin Welschof to its Board of Directors, marking a significant milestone for TCR-T cell therapy in cancer treatment.
Ask a question
How does Anocca's progress in TCR-T cell therapy compare to other cancer immunotherapy companies?
How might Martin Welschof's expertise contribute to the advancement of TCR-T cell therapy for cancer treatment?
What potential impact could the GMP license have on Anocca's clinical trials and manufacturing capabilities?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage